Literature DB >> 27381489

Delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) and T2 mapping at 3T MRI of the wrist: Feasibility and clinical application.

Christoph Rehnitz1, Bastian Klaan1, Iris Burkholder2, Falko von Stillfried3, Hans-Ulrich Kauczor1, Marc-André Weber1.   

Abstract

PURPOSE: To assess the feasibility of delayed gadolinium-enhanced magnetic resonance imaging (MRI) of cartilage (dGEMRIC) and T2 mapping for biochemical imaging of the wrist at 3T.
MATERIALS AND METHODS: Seventeen patients with wrist pain (mean age, 41.4 ± 13.1 years) including a subgroup with chondromalacia (n = 11) and 15 healthy volunteers (26.0 ± 2.2 years) underwent dGEMRIC and T2 mapping at 3T. For dGEMRIC, the optimum time window after contrast-injection (gadopentetate dimeglumine) was defined as the plateau of the T1 curve of repeated measurements 15-90 minutes postinjection and assessed in all volunteers. Reference values of healthy-appearing cartilage from all individuals and values in areas of chondromalacia were assessed using region-of-interest analyses. Receiver-operating-characteristic analyses were applied to assess discriminatory ability between damaged and normal cartilage.
RESULTS: The optimum time window was 45-90 minutes, and the 60-minute timepoint was subsequently used. In chondromalacia, dGEMRIC values were lower (551 ± 84 msec, P < 0.001), and T2 values higher (63.9 ± 17.7, P = 0.001) compared to healthy-appearing cartilage of the same patient. Areas under the curve did not significantly differ between dGEMRIC (0.91) and T2 mapping (0.99; P = 0.17). In healthy-appearing cartilage of volunteers and patients, mean dGEMRIC values were 731.3 ± 47.1 msec and 674.6 ± 72.1 msec (P = 0.01), and mean T2 values were 36.5 ± 5 msec and 41.1 ± 3.2 msec (P = 0.009), respectively.
CONCLUSION: At 3T, dGEMRIC and T2 mapping are feasible for biochemical cartilage imaging of the wrist. Both techniques allow separation and biochemical assessment of thin opposing cartilage surfaces and can distinguish between healthy and damaged cartilage. LEVEL OF EVIDENCE: 3 J. Magn. Reson. Imaging 2017;45:381-389.
© 2016 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  3T MRI; T2 mapping; cartilage; dGEMRIC; wrist

Mesh:

Substances:

Year:  2016        PMID: 27381489     DOI: 10.1002/jmri.25371

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  5 in total

1.  Cartilage quantification using contrast-enhanced MRI in the wrist of rheumatoid arthritis: cartilage loss is associated with bone marrow edema.

Authors:  Motoshi Fujimori; Satoko Nakamura; Kiminori Hasegawa; Kunihiro Ikeno; Shota Ichikawa; Kenneth Sutherland; Tamotsu Kamishima
Journal:  Br J Radiol       Date:  2017-07-14       Impact factor: 3.039

2.  T2 mapping of the trapeziometacarpal joint and triangular fibrocartilage complex: a feasibility and reproducibility study at 1.5 T.

Authors:  Vito Chianca; Domenico Albano; Renato Cuocolo; Carmelo Messina; Salvatore Gitto; Arturo Brunetti; Luca Maria Sconfienza
Journal:  Radiol Med       Date:  2019-12-20       Impact factor: 3.469

3.  Updates in Musculoskeletal Imaging.

Authors:  Erin C Argentieri; Darryl B Sneag; O Kenechi Nwawka; Hollis G Potter
Journal:  Sports Health       Date:  2018 Jul/Aug       Impact factor: 3.843

4.  Inter- and Intraobserver reproducibility of T2 relaxation times of the discus interpubicus: A feasibility study at 3 Tesla.

Authors:  Kai-Jonathan Maas; Maxim Avanesov; Azien Laqmani; Julius Weinrich; Markus Sauer; Michael G Kaul; Gerhard Adam; Marc Regier; Cyrus Behzadi
Journal:  PLoS One       Date:  2018-08-22       Impact factor: 3.240

5.  3-T T2 mapping magnetic resonance imaging for biochemical assessment of normal and damaged glenoid cartilage: a prospective arthroscopy-controlled study.

Authors:  Felix Wuennemann; Laurent Kintzelé; Alexander Braun; Felix Zeifang; Michael W Maier; Iris Burkholder; Marc-André Weber; Hans-Ulrich Kauczor; Christoph Rehnitz
Journal:  Sci Rep       Date:  2020-09-01       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.